|Description||NMS-P118 is a highly selective Poly(ADP-ribose) Polymerase 1 (PARP-1) inhibitor with excellent ADME, pharmacokinetic profiles and high efficacy in vivo originated by Nerviano Medical Sciences. It was found to be less myelotoxic in vitro than olaparib which is a dual PARP-1/-2 inhibitor. It was in preclinical trials for Breast cancer, but no development had been published yet.|
|Synonyms||NMS-P118; NMS-P 118; NMS P118. 2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator: Nerviano Medical Sciences|
Olaparib, also known as AZD-2281 or KU-59436, is a small-molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensiti...
AY-NH is a selective proteinase-activated receptor 4 (PAR4) receptor agonist peptide. It stimulates aggregation of rat and human platelets in vitro. It reduces ...
AZ0108 is an orally bioavailable, PARP1,2,6 inhibitor that causes a multi-polar spindle phenotype at double digit nM concentrations. AZ0108 has been utilized as...
3-Aminobenzamide is a competitive PARP inhibitor with Ki of 1.8 μM.
MK-4827 (R-enantiomer) is the R form of MK-4827, which is a PARP inhibitor developed for the treatment of ovarian cancer.
BMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. PARP inhibitor BMN-...
Rucaparib, also known as (AG-14699 or PF-01367338, is a tricyclic indole poly(ADP-Ribose) polymerase (PARP1) inhibitor with potential chemosensitizing, radiose...
BYK 49187 is a non-selective PARP inhibitor (pIC50 = 8.36 and 7.50 for cell-free recombinant PARP-1 and murine PARP-2, respectively).